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PURPOSE The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with 
small human epidermal growth factor receptor 2 (HER2)–positive breast cancer. The primary analysis of the 
Adjuvant Paclitaxel and Trastuzumab trial demonstrated a 3-year disease-free survival (DFS) of 98.7%. In this 
planned secondary analysis, we report longer-term outcomes and exploratory results to characterize the biology 
of small HER2-positive tumors and genetic factors that may predispose to paclitaxel-induced peripheral 
neuropathy (TIPN).
PATIENTS AND METHODS In this phase II study, patients with HER2-positive breast cancer with tumors 3 cm or 
smaller and negative nodes received paclitaxel (80 mg/m2) with trastuzumab for 12 weeks, followed by 
trastuzumab for 9 months. The primary end point was DFS. Recurrence-free interval (RFI), breast cancer–
specific survival, and overall survival (OS) were also analyzed. In an exploratory analysis, intrinsic subtyping by 
PAM50 (Prosigna) and calculation of the risk of recurrence score were performed on the nCounter analysis 
system on archival tissue. Genotyping was performed to investigate TIPN.
RESULTS A total of 410 patients were enrolled from October 2007 to September 2010. After a median follow-up 
of 6.5 years, there were 23 DFS events. The 7-year DFS was 93% (95% CI, 90.4 to 96.2) with four (1.0%) distant 
recurrences, 7-year OS was 95% (95% CI, 92.4 to 97.7), and 7-year RFI was 97.5% (95% CI, 95.9 to 99.1). 
PAM50 analyses (n = 278) showed that most tumors were HER2-enriched (66%), followed by luminal B (14%), 
luminal A (13%), and basal-like (8%). Genotyping (n = 230) identified one single-nucleotide polymorphism, 
rs3012437, associated with an increased risk of TIPN in patients with grade 2 or greater TIPN (10.4%).
CONCLUSION With longer follow-up, adjuvant paclitaxel and trastuzumab is associated with excellent long-term 
outcomes. Distribution of PAM50 intrinsic subtypes in small HER2-positive tumors is similar to that previously 
reported for larger tumors.
J Clin Oncol 37:1868-1875. 
INTRODUCTION
Longer-term follow-up of the large pivotal trials has
confirmed a dramatic and sustained benefit of the
addition of trastuzumab to standard adjuvant che-
motherapy in patients with early-stage, human epi-
dermal growth factor receptor 2 (HER2)–positive
breast cancer, reducing both the risk of recurrence
and death.1-3 Moreover, the benefits of trastuzumab
are independent of age, tumor size, nodal status, and
hormone receptor (HR) status.
Retrospective data suggest that patients with small,
node-negative HER2-positive tumors have recur-
rence rates that range from 5% to 30%.4,5 However,
randomized trials of adjuvant trastuzumab included
a limited number of patients with stage I disease. To
our knowledge, the Adjuvant Paclitaxel and Trastu-
zumab (APT) trial6 was the first study designed to
specifically address the appropriate treatment ap-
proach for patients with small, node-negative HER2-
positive breast cancer. This study was a single-arm
trial, because it was believed that a randomized study
would not be feasible given retrospective data sug-
gesting more than a minimal risk of recurrence for this
population. Furthermore, there was no standard
treatment at that time for patients with small node-
negative HER2-positive tumors to define a control arm.
The first report of the APT trial in 2015 after a median
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free from invasive disease of 98.7% (95% CI, 97.6 to 99.8)
and a low rate of serious adverse events.6 Because the
majority of patients included in this trial had HR-positive,
HER2-positive breast cancers, which are believed to be
associated with later recurrences,1,2 long-term follow-up of
this trial was important to better determine the true efficacy
of this regimen.
In addition, HER2-positive breast cancer is a biologically
heterogeneous disease,7 with different treatment sensitiv-
ities and survival outcomes. Work looking at larger HER2-
positive breast cancers has shown that all four intrinsic
molecular subtypes can be identified by gene expression
analyses.8 However, molecular profiling of small HER2-
positive tumors is largely unknown, and we sought to
better characterize these small, node-negative tumors.
In this planned secondary analysis of the APT trial, we
report the updated results on 7-year disease-free survival
(DFS), recurrence-free interval (RFI), breast cancer–
specific survival (BCSS), and overall survival (OS). We also
report some exploratory analyses that include PAM50 in-
trinsic subtyping and risk of recurrence (ROR) score per-
formed on the available archival tissue, to better characterize
this patient population with small, node-negative HER2-
positive disease, because it may provide deeper insights
into potential therapeutic approaches. We also evaluated
genotyping for the association of genetic variants and
paclitaxel-induced peripheral neuropathy (TIPN), given that
this is one of the most burdensome long-term effects of
paclitaxel-containing regimens, and efforts to predict and
prevent such toxicity are warranted.
PATIENTS AND METHODS
Study Design and Patient Population
The APT study was a multicenter, single-arm, investigator-
initiated phase II trial. Details of the study design and study
population have been previously reported.6 Eligible patients
had HER2-positive breast cancer, pathologically confirmed
by local testing either through immunohistochemistry 3+
intensity or amplification of the HER2 gene on fluorescence
in situ hybridization 2.0 or greater. Primary invasive tumor
had to measure 3.0 cm or smaller in the greatest di-
mension, and patients had to have node-negative disease
(although the protocol was amended in June 2, 2009 after
188 patients enrolled to allow patients with a single
micrometastatic node [Data Supplement]). The protocol
required patients to have a left ventricular ejection fraction
of at least 50% (by echocardiography or multiple-gated
acquisition). Other requirements included no prior myo-
cardial infarction or uncontrolled hypertension, no neu-
ropathy higher than grade 1, no prior malignancy within the
past 5 years, and no prior history of invasive breast cancer.
Procedures
Adjuvant treatment consisted of weekly paclitaxel (80 mg/m2)
plus weekly trastuzumab for 12 weeks followed by
single-agent trastuzumab every 3 weeks for a total of 13
doses. Genentech provided funding for the study, but
paclitaxel and trastuzumab were commercially supplied.
Adjuvant endocrine therapy was recommended as per
institutional standard for women with HR-positive tu-
mors after the completion of paclitaxel therapy. Adjuvant
radiation therapy was also performed according to local
institutional standards. Patients could be treated with
conventional post-chemotherapy whole-breast radiation or
partial breast radiation administered by external beam or
brachytherapy.
All patients adhered to the same schedule of follow-up
visits. Left ventricular ejection fraction by echocardiography
or multitargeted acquisition scanning was required at
baseline, 12 weeks, 6 months, and 1 year after the start of
protocol treatment. Clinical assessments after finishing
trastuzumab monotherapy were scheduled every 6 months
for the first 4 years and then annually during years 5 to 10
after study enrollment or until the end point was reached.
An appropriate screening of residual breast tissue per-
formed at least yearly was required. The institutional review
board at each participating institution approved the study,
and written informed consent from all the trial participants
was provided before the study entry. A second consent was
obtained from patients for extended follow-up.
Statistical Considerations
Details of the statistical design were published previously.6 The
primary end point was DFS, which is the time from study
enrollment to the first of the following events that define
a failure: locoregional ipsilateral recurrence, contralateral in-
vasive breast cancer, distant recurrence, or death from any
cause, as defined by the Standardized Efficacy Endpoints
criteria.9 Participants who were alive and free from recurrence
were censored at the date of the last follow-up. For patients
who did not consent for additional follow-up, their survival time
was censored at their off-study dates. Exploratory survival end
points included RFI, BCSS, and OS. RFI was defined as the
time from study enrollment to the first documentation of dis-
ease recurrence, including invasive locoregional recurrence or
distant recurrence, and death as a result of breast cancer.
BCSS was defined as the time from study enrollment until
death as a result of breast cancer. OS was the time from study
enrollment until death as a result of any cause.
In our primary analysis, a Poisson test was used to evaluate
the failure rate at 3 years against a null hypothesis of 9.2%
using a one-sided type I error of 0.05. The planned sample
size was 400 patients, with interim futility analyses after 225
and 800 patient-years of follow-up and a final analysis after
1,600 patient-years of follow-up. Under this design, the
probability of rejecting the null was 0.95 if the true 3-year
failure rate is 5%. In this update analysis, the Kaplan-Meier
method was used in estimating the survival function for
primary and exploratory end points, and point estimates are
reported with two-sided 95% CIs.
PAM50 Intrinsic Subtype Analysis and ROR
Score Calculation
Hematoxylin and eosin–stained slides from formalin-fixed
paraffin-embedded (FFPE) surgical specimens were ex-
amined to confirm the presence of invasive tumor and to
determine the minimum surface area for scraping and
tumor enrichment. Total RNAwas isolated from 5-mm-thick
FFPE slides for each tumor specimen using the Qiagen
FFPE kit for RNA isolation from FFPE tissue (Qiagen, Hilde,
Germany) following the manufacturer’s protocol. RNA was
quantified using the NanoDrop 2000 spectrophotometer
(Thermo Fisher Scientific Waltham, MA). A minimum of
200 ng of total RNA was used to measure the expression of
the PAM50 subtype predictor genes. PAM50 gene ex-
pression analysis was conducted on the nCounter gene
expression platform (NanoString Technologies, Seattle, WA).
Data were analyzed using the Prosigna algorithm (Nano-
String Technologies) to determine the intrinsic subtype calls
(luminal A, luminal B, HER2-enriched, or basal-like) and to
generate ROR scores by mapping data to a validated
subtype-based riskmodel as previously described.10,11 Quality
assessment and normalization were performed in nSolver 4.0
from NanoString Technologies, as per the manufacturer’s
instructions.
Genotyping and Statistical Analysis for the Association of
Genetic Variants and TIPN
Top candidate germline single-nucleotide polymorphisms
(SNPs) for TIPN were selected from prior correlative
genome-wide analyses of TIPN in Eastern Cooperative
Oncology Group trial E510312 and further evaluated here.
All 51 candidate SNPs had a P value , .001 in the E5103
analysis, had linkage disequilibrium support, were from
unique regions of the genome, and were confined to pa-
tients of European ancestry.12 The SNPs were genotyped
using blood DNA derived from APT trial with a QuantStudio
12K Flex OpenArray AccuFill System (Thermo Fisher
Scientific) platform. SNPs were removed from the analysis if
the call rate was less than 95%, minor allele frequency less
than 3%, or the Hardy-Weinberg equilibriumP value, .001.
A case-control analysis was performed for those of self-
defined white race. Cases were defined as patients who
received at least one dose of paclitaxel and experienced
grade 2 or greater TIPN during treatment. Patients without
TIPN served as controls. Logistic regression model was used
in the statistical analysis. Age and body surface area were
used as covariates, similar to our prior analyses.12
RESULTS
Between October 9, 2007, and September 3, 2010, 410
patients were enrolled in the study and 406 started protocol
therapy (Fig 1). Baseline patient characteristics are listed in
Table 1. Overall, median age at enrollment was 55 years
(range, 24 to 85 years), and most patients (67%) had HR-
positive disease. Fifty percent of patients had tumors
1.0 cm or smaller, most of which were T1b. Only 9% of
patients had tumors larger than 2 cm and up to 3 cm. Mean
tumor size was 1.1 cm.
The results reported in our primary analysis published in
2015 included all data available as of April 21, 2014, with
1,605 patient-years of follow-up. The 3-year rate of DFS
was 98.7% (95% CI, 97.6 to 99.8), with 12 DFS events
reported (two distant recurrences). The long-term results
reported here are from all data available as of November 11,
Assessed for eligibility
(N = 410)
Allocated to intervention (n = 406)
   Did not receive intervention   (n = 0)
Discontinued intervention (n = 50)
   Protocol specified toxicity (n = 24)
   Toxicity not protocol specified   (n = 6)
   Intercurrent illness   (n = 1)
   Patient decision (n = 13)
   Physician decision   (n = 4)
   Disease recurrence   (n = 1)
   Unknown reason   (n = 1)
Discontinued follow-up (n = 69)
   Death (n = 14)
   Withdrew from study (n = 22)
   Lost to follow up (n = 20)
   Patients did not consent to
      follow-up beyond 5 years
Analyzed    (n = 406)
Excluded (n = 4)
   Did not meet inclusion criteria (n = 1)






FIG 1. Trial enrollment and
follow-up.
2016, which includes 2,390 patient-years of follow-up. After
a median follow-up of 6.5 years (range, 0.02 to 8.9 years),
there were 23 DFS events observed: five locoregional re-
currences (1.2%), four distant recurrences (1%), six new
contralateral breast cancers (1.5%), and eight deaths without
documented recurrence (2%; Table 2). The 7-year DFS was
93.3% (95%CI, 90.4 to 96.2) for the overall population (Fig 2);
in patients withHR-positive tumors, the 7-year DFSwas 94.6%
(95% CI, 91.8 to 97.5), and among HR-negative patients, the
7-year DFS was 90.7% (95% CI, 84.6 to 97.2).





Assessed (n = 278)
Patients Without PAM50
Assessed (n = 128) P*
Age group, years
, 50 132 (33) 79 (28) 53 (41) .02
50-59 137 (34) 101 (36) 36 (28)
60-69 96 (24) 64 (23) 32 (25)
$ 70 41 (10) 34 (12) 7 (5)
Sex
Female 405 (100) 277 (100) 128 (100) 1.00
Male 1 (, 1) 1 (, 1) 0 (0)
Race
White 351 (86) 242 (87) 109 (85) .88
Black or African American 28 (7) 17 (6) 11 (9)
Asian 11 (3) 8 (3) 3 (2)
Other 16 (4) 11 (4) 5 (4)
Size of primary tumor, cm
T1mi (# 0.1) 9 (2) 1 (, 1) 8 (6) , .001
T1a (0.1 to # 0.5) 68 (17) 29 (10) 39 (30)
T1b (. 0.5 to # 1.0) 124 (31) 81 (29) 43 (34)
T1c (. 1.0 to # 2.0) 169 (42) 137 (49) 32 (25)
T2 (. 2.0 to # 3.0) 36 (9) 30 (11) 6 (5)
Histologic grade
I: Well differentiated 44 (11) 26 (9) 18 (14) .02
II: Moderately differentiated 131 (32) 88 (32) 43 (34)
III: Poorly differentiated 228 (56) 164 (59) 64 (50)
Unknown 3 (1) 0 (0) 3 (2)
ER status
Positive 260 (64) 188 (68) 72 (56) .03
Negative 141 (35) 88 (32) 53 (41)
Borderline 5 (1) 2 (1) 3 (2)
PR status
Positive 201 (50) 150 (54) 51 (40) .02
Negative 196 (48) 123 (44) 73 (57)
Borderline 8 (2) 5 (2) 3 (2)
Unknown 1 (, 1) 0 (0) 1 (1)
HR status
Positive 272 (67) 196 (70) 76 (59) .03
Negative 134 (33) 82 (30) 52 (41)
NOTE. Data given as No. (%).
Abbreviations: ER, estrogen receptor; HR, hormone receptor; PR, progesterone receptor.
*P values were obtained using Fisher’s exact test.
Seven-year RFI, which includes distant recurrence, death
from breast cancer, and invasive locoregional recurrence,
was 97.5% (95%CI, 95.9 to 99.1%). Seven-year BCSS was
98.6% (95% CI, 97.0 to 100%), and 7-year OS was 95.0%
(95% CI, 92.4 to 97.7%; Table 3).
PAM50 gene expression profiling was successfully per-
formed in 278 patients (Appendix Fig A1, online only). The
overall cohort and the cohort of the subset of patients with
PAM50 data presented similar baseline characteristics
(Table 1), although there were significantly more patients
with larger and poorly differentiated tumors in the cohort of
PAM50 assessed than in the overall cohort. Distribution of
PAM50 subtypes is listed in Table 4. The majority of tumors
were classified as HER2 enriched (65.5%), followed by
luminal B (13.7%), luminal A (12.6%), and basal-like
(7.9%). Subtype distribution differed significantly by HR
status (Table 4). A greater percentage of HR-negative
patients were HER2 enriched (84% v 58%, P , .001)
and basal-like (13% v 6%; P , .001) than in the HR-
positive cohort, and no cases of luminal B were found in
HR-negative tumors. The low event rate observed prevents
making statistical inferences on the prognostic value of
molecular intrinsic subtypes. Appendix Table A1 (online
only) lists the pathologic characteristics and molecular
intrinsic subtype of patients with an RFI event.
Finally, we evaluated the ROR scores, available in 264
patients. Only nine samples (3.4%) were categorized as low
risk, 56 (21.2%) were classified as intermediate risk, and
the majority of tumors (199; 75.4%) were categorized as
high risk. ROR scores on the basis of the intrinsic subtype
are listed in Appendix Table A2 (online only). As expected,
luminal A tumor samples showed significantly lower me-
dian ROR scores than HER2-enriched, luminal B, and
basal-like tumor samples (50 v 76, 72.5, and 72.5, re-
spectively; P, .001). All tumor samples categorized as low
risk by ROR score were luminal A. However, most luminal A
tumors had an intermediate ROR score, and none of the
luminal A tumors had high ROR score. In contrast, the
majority of HER2-enriched, luminal B, and basal-like tumor
samples were classified as high risk by ROR score.
Regarding TIPN, 230 patients had evaluable genetic data.
In this subgroup, there were 24 cases of grade 2 or greater
TIPN (10.4%); no grade 4 neurotoxicity was reported (in
this cohort of patients or in the overall population of the
study). Fifty of the planned 51 SNPs passed quality control
TABLE 2. DFS Events Observed
DFS Event No. (%)
Time to Event (months),
Median (range)
Any recurrence or death 23 (5.7)
Local/regional recurrence 5 (1.2)
Ipsilateral axilla (HER2 positive) 3 20 (12-54)
Ipsilateral breast (HER2 positive) 2 51 (37-65)
New contralateral primary breast cancer 6 (1.5)
HER2 positive 1 56
HER2 negative 3 36 (12-59)
Unknown 2 87 (84-90)
Distant recurrence 4 (1.0) 53 (27-63)
Death
Non–breast-cancer related 8 (2.0) 66 (13-71)
Abbreviations: DFS, disease-free survival; HER2, human epidermal growth factor
receptor 2.
Negative 10 90.7 84.6% to 97.2%
Positive 13 94.6 91.8% to 97.5%


















406 388 385 378 362 347 247 120 34 0
Point Est (%) 95% CI (%) No. of events
3-yr DFS 98.5 97.2 to 99.7 6
5-yr DFS 96.3 94.4 to 98.2 14



















134 126 126 123 119 111 73 43 10 0
272 262 259 255 243 236 174 77 24 0
B
Stratum 7-yr DFS (%) 95% CI (%)No. of Events
FIG 2. Disease-free survival (DFS). (A) Kaplan-Meier plot of DFS in the intention-to-treat population. (B) DFS according to hormone-receptor status.
Abbreviations: neg, negative; Point est, point estimate; pos, positive.
and were evaluated. One SNP, rs3012437, was associated
with an increased risk of TIPN for grade 2 or greater TIPN
after correction for age and body surface area (P = .024;
odds ratio, 2.1).
DISCUSSION
This 7-year follow-up report of paclitaxel and trastuzumab
for patients with small, node-negative HER2-positive breast
cancer demonstrates few disease recurrences with even
longer follow-up and further supports the use of this reg-
imen for adjuvant therapy for this patient population. The
3-year and 7-year DFS in the APT trial were 98.7% and
93%, respectively, with just four distant recurrences at
7 years (1%). Many of the DFS events were contralateral
cancers or unrelated deaths. When evaluating outcomes in
relatively low-risk patients, it is important to acknowledge
that DFS captures events that do not necessarily reflect
a recurrence from the initial breast cancer. As we follow
patients over time, the frequency of these events increases.
As such, RFI, which includes invasive locoregional and dis-
tant recurrences and deaths as a result of breast cancer, may
better describe the relevant event rate in this patient pop-
ulation. The 7-year RFI in the APT trial was 97.5%, suggesting
few events related to the initial breast cancer diagnosis.
Molecular profiling of this subset of patients with small
HER2-positive breast cancers by PAM50 identified all four
intrinsic molecular subtypes. Most tumors were identified
as HER2 enriched (66%), and, as expected, subtype
distribution differed significantly by HR status. A greater
percentage of HR-negative tumors were HER2-enriched
and basal-like. However, the HER2-enriched subtype was
the predominant subtype not only in the HR-negative
cohort but also in HR-positive tumors (84% and 58%,
respectively). These results are in accordance with the
PAMELA (PAM50 HER2-enriched Subtype as a Predictor
of Response to Dual HER2 Blockade in HER2-positive Early
Breast Cancer) trial,13 wheremost tumors were classified as
HER2 enriched (67%) as well. In contrast, the percentage
of HER2-enriched subtype at baseline in the Cancer and
Leukemia Group B (CALGB) 40601 study7 was lower and
was similar to percentages of luminal A and luminal B
tumors. Moreover, among patients with HR-positive, HER2-
positive tumors, the luminal subtypes were found to be the
most prevalent.7 The APT and PAMELA trials used the
same nCounter platform to perform molecular profiling,
whereas the RNA-seq method was used in the CALGB
40601 study. These data confirm that HER2-positive breast
cancer is indeed a heterogeneous disease, not fully re-
capitulated by HR status, and that smaller HER2-positive
tumors have a similar distribution of intrinsic subtypes as
larger tumors. Therefore, the biology of these smaller tu-
mors may not be dissimilar to larger tumors. Although it is
known that intrinsic subtypes play a key role in determining
response to anti-HER2 treatment,7,13 data from this study
are not able to assess the association of subtype with long-
term outcomes, given the low event rate. Interestingly,
though, the majority (71%) of the tumor samples were
categorized as high ROR (. 60). Previous work in HR-
positive, HER2-negative breast cancer suggests high ROR
is associated with higher risk of recurrence;14,15 however,
given the low event rate seen in this study, these data may
not be applicable to patients with small node-negative,
HER2-positive tumors who receive therapy.
TIPN is an important toxicity that compromises paclitaxel
treatment efficacy and patients’ quality of life. To date, there
are only minimally effective treatments, and there are no
clinically implemented predictive biomarkers available for
TIPN. Previously, SNPs associated with TIPN were iden-
tified using two large phase III adjuvant breast cancer trials,
E5103 and E1199.12 In the current study, we evaluated the
same top 51 SNPs evaluated in the genome-wide asso-
ciation study from E510312 and found that rs3012437,
which is in the uncharacterized LOC154449 region of
chromosome 6, is associated with the risk of grade 2 or
greater TIPN. Thus, this represents, to our knowledge, the
first independent association between rs3012437 and the
risk of TIPN warranting additional evaluation, because this















Risk Rate (95% CI)
3 3 378 99.2 (98.4 to . 99.9) 0 386 — 1 386 99.7 (99.2 to . 99.9)
5 7 347 98.1 (96.8 to 99.5) 1 362 99.7 (98.1 to . 99.9) 5 362 98.7 (97.5 to 99.8)
7 9 120 97.5 (95.9 to 99.1) 3 127 98.6 (97.0 to . 99.9) 14 127 95.0 (92.4 to 97.7)
Abbreviations: BCSS, Breast Cancer-Specific Survival; OS, overall survival; RFI, Recurrence-Free Interval.
TABLE 4. Distribution of PAM50 Intrinsic Molecular Subtypes at Baseline in the








HER2-enriched 183 (66) 114 (58) 69 (82)
Luminal B 38 (14) 38 (19) 2 (3)
Luminal A 35 (12) 33 (17) 0
Basal-like 22 (8) 11 (6) 11 (15)
NOTE. Data given as No. (%).
Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone 
receptor.
might ultimately affect treatment decision making in this
population at high risk of TIPN.
The APT study has several strengths and limitations. It is
a phase II study with a large sample size and long-term
follow-up that reaffirms the results reported earlier. We are
aware, however, that a randomized trial would have been
ideal. As previously mentioned, there were feasibility
concerns about the most appropriate control arm, because
no standard of treatment existed at that time in this pop-
ulation. The higher frequency of HR-positive tumors in our
study (67%) than in the pivotal adjuvant trastuzumab trials
(51% to 54%) could have implications for late recurrences,
because the risk of recurrence in the first years after di-
agnosis is higher in HR-negative tumors than in HR-positive
ones. It is of interest, however, that a high percentage of the
HR-positive tumors were also HER2 enriched. Whether
these HR-positive and HER2-enriched tumors are at higher
risk of late recurrence is unknown. In any case, the long-
term follow-up data in this updated report confirm that
these patients continue to do well and uphold this treatment
strategy as adequate for small HER2-positive breast can-
cers. It is important to note, however, that this study does
not provide data to support the use of trastuzumab-based
therapy in all patients with small HER2-positive tumors.
There will be patients, particularly most patients with pT1a
and some with pT1b, who may not require adjuvant
trastuzumab-based chemotherapy, and a balance be-
tween a patient’s risk of recurrence and potential tox-
icities must be considered. Work is ongoing to see if
a potentially less-toxic therapy, such as trastuzumab
emtansine (T-DM1), may be an alternative treatment
strategy for patients with small HER2-positive tumors. The
ATEMPT trial (Adjuvant Trastuzumab Emtansine vs Paclitaxel/
Trastuzumab) (ClinicalTrials.gov identifier: NCT01853748) is
an ongoing randomized phase II trial of T-DM1 versus
adjuvant paclitaxel and trastuzumab for patients with stage
I HER2-positive breast cancer that is comparing clinically
relevant toxicities between the two arms and assessing DFS
for patients receiving T-DM1. This study has completed
accrual, and results are pending.
In conclusion, after a median follow-up of 6.5 years, pa-
tients with small, HER2-positive breast cancer treated with
adjuvant paclitaxel and trastuzumab continued to dem-
onstrate excellent outcomes. These long-term data support
the use of adjuvant paclitaxel and trastuzumab as a treat-
ment option for patients with stage I, HER2-positive breast
cancer. This regimen represents an important step forward
in de-escalating therapy to preserve quality of life while
achieving excellent outcomes for patients with HER2-
positive breast cancer.
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FIG A1. Tumor sample analyses. (*) Tumors less than 4 mm were
excluded (insufficient invasive tissue). (†) NanoString set a pre-
defined threshold to maintain the integrity of the subtyping call. A
100-count Geomean for the housekeeping genes (HKs) is the
minimal amount needed to generate a confident subtype call. The
algorithm requires data above the background to make a reason-
able call of subtype, and HK was used as a marker for the rest of the
targets. Cases with borderline HK Geomean were excluded from the
risk of recurrence (ROR) score evaluation. (‡) Five cases previously
incorrectly marked as failed subtyping were corrected and included
in the ROR scoring. Therefore, there is a total discrepancy of 14
cases between the number of cases with PAM50 (Prosigna) results
and number of cases with ROR scores. QNS, quantity not sufficient.
TABLE A1. Baseline Characteristics of Patients With an RFI Event
Age at Study






Intrinsic Subtype RFI Event
RFI PAM50 Intrinsic
Subtype
40 3 Positive 1.5 QNS Locoregional recurrence QNS
41 3 Positive 0.8 QNS Locoregional recurrence HER2 enriched
72 3 Negative 1.9 QNS Locoregional recurrence HER2 enriched
56 2 Positive 0.8 QNS Locoregional recurrence QNS
49 3 Positive 0.8 Luminal B Locoregional recurrence Luminal A
58 3 Positive 1.6 Luminal B Distant recurrence QNS
46 3 Negative 1.2 HER2 enriched Distant recurrence HER2 enriched
55 3 Positive 0.9 Luminal B Distant recurrence Luminal B
73 3 Positive 2.5 HER2 enriched Distant recurrence QNS
Abbreviations: HER2, human epidermal growth factor receptor 2; QNS, quantity not sufficient; RFI, recurrence-free interval.
TABLE A2. ROR Scores on the Basis of the Intrinsic Subtype (N = 281)
Subtype No. (%) ROR, Median (range) Low (£ 40) Intermediate (41-60) High (> 60)
HER2-enriched 173 (65.5) 76 (46-100) 0 21 152
Luminal B 38 (14.4) 72.5 (51-94) 0 7 31
Luminal A 33 (12.5) 50 (8-59) 9 24 0
Basal-like 20 (7.6) 72.5 (51-91) 0 4 16
Abbreviations: HER2, human epidermal growth factor receptor 2; ROR, risk of recurrence.
